- /
- Supported exchanges
- / US
- / ABBV.NYSE
AbbVie Inc (ABBV NYSE) stock market data APIs
AbbVie Inc Financial Data Overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with AbbVie Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get AbbVie Inc data using free add-ons & libraries
Get AbbVie Inc Fundamental Data
AbbVie Inc Fundamental data includes:
- Net Revenue: 61 160 M
- EBITDA: 29 254 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: 3.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AbbVie Inc News
New
Australia Drug Delivery Devices Market Trends by Type of Product, Application Area and End-user - Forecast to 2035
Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Australia Drug Delivery Devices Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Application Area and End-us...
IIT2026 CONFERENCE BRINGS GLOBAL THOUGHT LEADERS TO LONG BEACH
LONG BEACH, Calif., April 7, 2026 /PRNewswire/ -- The IIT2026 Global Conference is bringing together top minds in leading industries from the U.S. and India, from April 22-25 this year at the Long Bea...
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
Quick Read JPMorgan maintains its Overweight rating and $260 price target on AbbVie (ABBV), calling the pullback a buying opportunity as the firm sees upside to consensus estimates backed by strong S...
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
The Allergan Medical Institute (AMI) Austin location strengthens the national training network with comprehensive, hands-on education. The Orange County and Atlanta AMI centers continue delivering bes...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.